Virpax Q1 2024 operating loss $3.2M, cash $1.9M; Probudur study shows tolerability

Virpax Pharmaceuticals, Inc.

2024-Q1 EPS reported -$2.75

Operating loss of $3.2M compares to $1.5M in Q1 2023, driven by higher G&A and R&D spend.
Cash at March 31, 2024 was approximately $1.9M.
Probudur maximum tolerated dose study: all doses well-tolerated, no noteworthy effects on body weight or clinical parameters.
Litigation settlement with Sorrento Therapeutics approved by bankruptcy court; initial payment made March 18, 2024.
Pilot study of Probudur in rat model showed reduction in incision-induced pain behaviors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Virpax Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001213900-24-042322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.